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Many drug discovery projects rely on commercial compounds to discover active leads.
However, current commercial libraries, with mostly synthetic compounds, access a small
fraction of the possible chemical diversity. Natural products, in contrast, possess a vast
structural diversity and have proven to be an outstanding source of new drugs. Several
chemoinformatic analyses of natural products have demonstrated their diversity and
structural complexity. However, to our knowledge, the scaffold content and structural
diversity of fungal secondary metabolites have never been studied. Herein, the scaffold
diversity of 223 fungal metabolites was measured and compared to the diversity of
approved drugs and commercial libraries for HTS containing natural, synthetic, and
semi-synthetic compounds. In addition, the global diversity of the fungal isolates was
assessed and compared to other reference data sets using Consensus Diversity Plots,
a chemoinformatic tool recently developed. It was concluded that fungal secondary
metabolites are cyclic systems with few ramifications and more diverse than the
commercial libraries with natural products and semi-synthetic compounds. The fungal
metabolites data set was one of the most structurally diverse, containing a large
proportion of different and unique scaffolds not found in the other compound data sets
including ChEMBL. Therefore, fungal metabolites offer a rich source of molecules suited
for identifying diverse candidates for drug discovery.
Keywords: chemical space, cheminformatics, consensus diversity plots, generative topographic mapping,
molecular diversity, natural products, fungal metabolites
INTRODUCTION
With a dramatic increase in commercially available compounds and the accessibility to high
throughput screening (HTS), many current drug discovery projects rely on commercial libraries
to uncover novel active compounds against different molecular targets (Roy et al., 2010). However,
numerous analyses have revealed that libraries with poor diversity undermine HTS productivity,
thus reducing the probability to find active compounds. Many research groups are investing in
enhancing their collections by adding compounds with different chemotypes rather than simply
increasing the size of their compound libraries (Macarron et al., 2011). Although, a highly diverse
compound library would be considered the most profitable starting point to find new leads, the
term diversity generates constant debate since the optimum composition of a library depends
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on the research objectives. Nonetheless, it has been shown that
a diverse compound library is directly linked to a higher hit
discovery rate than a similar sized combinatorial library with
limited structural variation (Harper et al., 2004).
Natural products have a vast diversity and are rich sources of
bioactive compounds (Hong, 2011). Several studies have shown
that natural products and drugs approved by the United States
Food and Drug Administration (FDA) share regions of chemical
space and have similar molecular properties (Gu et al., 2013).
Moreover, natural products have novel and complex chemotypes
(Yongye et al., 2012) and new chemical structures from natural
origin are constantly being discovered (Rosen et al., 2009).
Therefore, natural products offer an excellent opportunity to
enrich chemical libraries (Gu et al., 2013).
Specifically, natural products derived from fungi have been
the source of many important approved drugs with diverse
mechanisms of action (Pearce, 1997; Pearce et al., 2009). Fungi
are widely found in nature and are able to generate novel
structures with chemical diversity from simple starting materials
including organic acids, sugars, amino acids, terpenes, and
bases such as purines and pyrimidines. Gene sequencing has
demonstrated there are multiple “silent” biosynthetic pathways,
meaning there is genetic information that encodes for the
synthesis of new products that have not been studied. Taken
together with the vast number of unstudied fungal species in
the world (Hawksworth and Rossman, 1997), fungi are a highly
promising source for new medicines.
The number of in silico analyses of fungal metabolites is still
limited but the interest in this area is increasing. El-Elimat et al.
(2012) studied the chemical space of 105 compounds isolated
from filamentous fungi using nine molecular descriptors, and
compared them to other natural products and FDA-approved
anticancer drugs. In that work it was concluded that fungal
metabolites had a high overlap with the chemical space of
anticancer drugs, which was an encouraging finding for the
ongoing efforts to discover active anticancer compounds of
fungal origin (Kinghorn et al., 2016). Gonzalez-Medina et al.
(2016) analyzed a larger data set with 207 fungal isolates,
adding more information on structural complexity and diversity
of the fungal metabolites. In that work fungal metabolites
were demonstrated to be more complex than approved drugs
and commercial libraries, and as complex as compounds used
in the food industry, Generally Recognized as Safe (GRAS).
Those results suggested that fungal metabolites could be
selective and have an appropriate toxicity profile. Furthermore,
fungal metabolites had drug-like properties and covered similar
Abbreviations: AUC, area under the curve; CDP, Consensus Diversity Plot; CSR
curves, cyclic system retrieval curves; FDA, Food and Drug Administration;
FEMA, Flavor and Extract Manufacturers Association; GRAS, Generally
Recognized as Safe; GTM, Generative Topographic Mapping; HBA, hydrogen
bond acceptors; HBD, hydrogen bond donors; HTS, high throughput screening;
Log P, the octanol/water partition coefficient; MACCS, Molecular ACCess System;
MEQI, Molecular Equivalent Indices; MOE, Molecular Operating Environment;
MW, molecular weight; N, number of chemotypes: Nsing, number of singletons;
PCA, Principal Component Analysis; RBF, Radial Basis Function; RTB, number
of rotatable bonds; SE, Shannon entropy; SSE, scaled Shannon Entropy; TPSA,
topological polar surface area.
chemical space of approved drugs as well as unexplored areas.
However, the scaffold composition and diversity of fungal
metabolites has not been studied in a systematic and quantitative
manner.
The goal of this work was to measure the scaffold
content and diversity of an in-house library with 223 fungal
metabolites. Five data sets were used as reference: non-
anticancer drugs approved by the FDA, anticancer drugs
approved by the FDA, compounds based on the Flavor and
Extract Manufacturers Association of the United States (FEMA),
and two commercial libraries containing natural products
and semi-synthetic compounds. Additional criteria, including
molecular properties and fingerprints were used to obtain a
complete scaffold analysis and to compare datasets of different
size containing cyclic and acyclic compounds. Consensus
Diversity Plot (CDP) (González-Medina et al., 2016), a novel
chemoinformatic tool developed to analyze the global diversity of
compound data sets, was employed to compare the total diversity
of fungal metabolites with other reference collections.
METHODS
Data Sets
The chemotype diversity was analyzed for a unique in-house
library of 223 fungal metabolites (El-Elimat et al., 2012;
Gonzalez-Medina et al., 2016). For reference, five data sets
containing between 76 and 2,500 compounds were included
in the analysis: compounds based on the FEMA GRAS list
(hereafter referred to as GRAS; Burdock et al., 2006; Medina-
Franco et al., 2012); FDA approved drugs obtained from
DrugBank, version 4.0 (Wishart et al., 2006; Law et al.,
2014) subdivided into: anticancer and non-anticancer drugs;
and two datasets from a commercial vendor (http://www.ac-
discovery.com) containing mostly natural products derived from
plants (MEGx) and semi-synthetic compounds (NATx). Table 1
summarizes all data sets used, including source and number
of unique compounds after data curation. Duplicates in each
data set were removed using Molecular Operating Environment
(MOE), version 2014.0 (MOE, 2016). The complete data set of
fungal metabolites is available upon request, the other data sets
TABLE 1 | Compound data sets analyzed in this work.
Data set Unique
compounds
Sources
Fungal metabolites 223 El-Elimat et al., 2012
Natural products screening
compounds (MEGx)
2,500 http://www.ac-discovery.com
Semi-synthetic screening
compounds (NATx)
2,500 http://www.ac-discovery.com
Generally Recognized as
Safe (GRAS)
2,249 Burdock et al., 2006;
Medina-Franco et al., 2012
Anticancer drugs from
DrugBank
76 Wishart et al., 2006; Law et al.,
2014
Non-anticancer drugs from
DrugBank
1,399 Wishart et al., 2006; Law et al.,
2014
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and the compounds information can be downloaded from the
supporting information (Data Sheet 2).
Scaffold Definition and Acyclic Molecules
The term scaffold is now used extensively to describe the core
structure of a molecule. Different ways to obtain the scaffold of
a molecule have been reviewed elsewhere (Brown and Jacoby,
2006; Yan et al., 2009). In this work the scaffolds were derived
with the methodology previously described by Johnson and Xu
(Xu and Johnson, 2002). Chemotypes were calculated with the
program Molecular Equivalent Indices (MEQI; Xu and Johnson,
2001, 2002) resulting in a code of five characters assigned to
each chemotype using a unique naming algorithm (Figure 1).
For this work, both acyclic and cyclic systems (hereafter
referred to as chemotypes) were used to compare the structural
diversity.
Chemotype Diversity
For each data set the number of unique chemotypes was recorded
as well as the number of chemotypes containing only one
compound. The fraction of chemotypes and singletons relative
to the number of molecules in the data set were analyzed.
Cyclic system retrieval (CSR) curves were computed for each
data set to analyze the distribution of chemotypes (Lipkus et al.,
2008). To generate the CSR curves, the fraction of chemotypes
was plotted on the X-axis and the fraction of compounds that
contain those chemotypes was plotted on the Y-axis. Information
such as the fraction of chemotypes required to retrieve a certain
percentage of the molecules in the database and the area under
the curve (AUC) can be obtained from these curves. For this
work CSR curves were characterized calculating the AUC and the
fraction of chemotypes required to retrieve 50% of the molecules
(F50). The F50 metric has been used as a measure of scaffold
diversity (Krier et al., 2006; Lipkus et al., 2008; Medina-Franco
et al., 2009; Yongye et al., 2012).
As previously reported, the concept of Shannon entropy
(SE) (Godden and Bajorath, 2007) was used to determine the
distribution of compounds in the n most populated chemotypes
based on histogram representations (Medina-Franco et al., 2009).
The SE of a population of P compounds in n systems is defined
as:
SE = −
∑n
i= 1
pilog2pi (1)
pi =
ci
P
(2)
where pi is the estimated probability, or frequency, of the
occurrence of a specific chemotype i in a population of P
compounds containing a total of n chemotypes and ci is the
number of molecules containing a particular chemotype. The
value of SE ranges from 0, when all the compounds have the same
chemotype, and it takes its maximum value when SE equals to
log2 n, meaning that all the compounds are evenly distributed
among the n chemotypes representing a highly diverse data set.
To normalize SE by the different most populated chemotypes
n, the scaled Shannon entropy (SSE) is defined as:
SSE =
SE
log2n
(3)
SSE values range from 0, when all the molecules in the data set
contain only one chemotype, to 1 indicating high diversity within
the n chemotypes. Here, different numbers of n (from 5 to 70)
were analyzed.
Fingerprints and Molecular Properties
The inter- and intra-molecular properties diversity for each data
set was analyzed based on structural fingerprints and molecular
properties. Molecular ACCess System (MACCS) keys (166-
bits) fingerprints were computed with MayaChem Tools (Sud,
2016) and R Studio scripts (Team, 2015). To compare the data
sets, six properties of pharmaceutical relevance were calculated
FIGURE 1 | Definition of scaffold used in this work. The cyclic system was obtained after iteratively removing the side chains of the entire molecule. Acyclic and
cyclic systems were considered for this work and were defined by a code of five characters.
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with MOE software: hydrogen bond donors (HBD), hydrogen
bond acceptors (HBA), the octanol/water partition coefficient
(LogP), molecular weight (MW), topological polar surface area
(TPSA), and number of rotatable bonds (RTB). These molecular
descriptors have been used previously to measure molecular
properties diversity (Gonzalez-Medina et al., 2016).
Similarity Coefficients
There are many ways in which the similarities between pairs
of molecules can be calculated. Here, we used two well-
known measures to compare discrete and continuous variables.
The Soergel distance function is a complement of Tanimoto
similarity coefficient (Owen et al., 2011), widely used for binary
fingerprints.
Tanimoto (x, y) = (
x.yT
x.xT + y.yT − x.yT
) (4)
Soergel (x, y) = 1− tanimoto (x, y) (5)
The similarity coefficient between data sets (duv) was calculated
with a Soergel-based inter-data set distance function, previously
described by Owen et al. (2011).
duv =
1
NuNv
∑Nu
i= 1
∑Nv
j= 1
soergel (xui , x
v
j ) (6)
where Nu and Nv are the number of molecules in data sets
Du and Dv, and x
u
i and x
v
j are the fingerprint vectors from the
compounds i or j of the fingerprint array for the data sets Du or
Dv, respectively. The diversity of the molecules within a single
data set (du) was calculated rearranging the Equation 6:
du =
2
N2u
∑Nu−1
i= 1
∑Nu
j= i+ 1
soergel (xui , x
u
j ) (7)
The distance (or dissimilarity) between any two data sets, Du
andDv, was computed using the Euclidean distance (Perez, 2005;
Karthikeyan and Vyas, 2014), Equation (8), as follows. Let xi be
the N-dimensional vector of molecular properties for molecule
i in data set Du; similarly, let yi be the N-dimensional vector
of molecular properties for molecule j in data set Dv. (For the
analyses in this article, 6 molecular properties where used, so N
= 6). Let the number of molecules in data sets Du and Dv be U
andV, respectively. Then the inter-data set distance between data
sets Du and Dv, was computed as introduced in Equation (9):
Euclidean (Xi, Yj) =
√∑N
k= 1
(Xik − Yjk)
2 (8)
Iuv =
1
UV
∑U
i= 1
∑V
j= 1
euclidean (Xi,Yj) (9)
Global Diversity Analysis with Consensus
Diversity Plots (CDPs)
CDPs have been designed to compare the diversity of compound
data sets analyzing, in two dimensions, four criteria of diversity
(González-Medina et al., 2016). Herein, we employed two
metrics to quantify structural diversity: MACCs keys/Soergel-
based distance, plotted on the X axis, and AUC, on the Y axis. The
third property analyzed in the CDPs was themolecular properties
intra-data set distance, calculated with Euclidean distance. This
property is represented in the plot by the color of each data
point: data sets in red had the highest Euclidean distances, i.e.,
are themost diverse, data sets in orange/brown have intermediate
diversity values and data sets in green are the least diverse. The
fourth property represented on this plot was the size of the data
sets. This property is represented by the relative size of the data
point representing each set; bigger data points correspond to data
sets with more compounds. Four regions, in different colors, can
be distinguished on the plot: the region in red contains the most
diverse data sets, i.e., this data sets are diverse either by their
scaffold content or if features of the entire molecule are analyzed
and compared using fingerprints; the white region shows the least
diverse data sets, i.e., these data sets were the least diverse by
scaffold content and fingerprints/similarity; blue, all data sets in
this region contain either acyclic compounds which are diverse if
the entire molecule is compared (i.e., using fingerprints) or data
sets containing cyclic systems for which side chains contribute
significantly to their diversity; yellow, this fourth region contains
data sets diverse by the number of different scaffolds with few
ramifications. To set the four regions on the plots we chose a
threshold for each axis: a value of 0.75 was chosen as the threshold
for the y axis, considering that the lowest AUC value a data set
could have is 0.5, if it is highly diverse by scaffolds, and the highest
AUC value it could have is 1; the threshold for the x axis was
the median of the Soergel intra-data set distance obtained from
MACCS keys fingerprints for each set, therefore this threshold is
specifically for the data sets analyzed in this work. As previously
discussed, other thresholds can be set up to define the quadrants
of the CDPs (González-Medina et al., 2016).
Visual Representation of the Chemical
Space
Two approaches were used to cluster and visualize the molecules
in the data sets based on their molecular properties and structural
features: Principal Component Analysis (PCA) (Jolliffe, 2002)
and Generative Topographic Mapping (GTM) (Osolodkin et al.,
2015). PCA is a technique often used to emphasize variation
and find patterns in a data set. The main disadvantage of PCA
is that it is a linear mapping technique and is unable to map
non-linear data. GTM is a nonlinear method that trains a Radial
Basis Function (RBF) neuronal network to produce a mapping
from an n-dimensional data space to a two dimensional latent
space (Owen et al., 2011; Gaspar et al., 2013). For further
explanation on each model, the reader is referred to the cited
papers (Gaspar et al., 2013, 2015). To represent the chemical
space using molecular fingerprints, a fingerprint array was
assembled from the MACCS key fingerprint results, consisting
of 166 bits in which each element is either 0 or 1 to indicate the
absence or presence, respectively, of structural elements in the
corresponding molecular structure. The six molecular properties
of pharmaceutical relevance (HBD, HBA, LogP, MW, TPSA, and
RTB) were arranged in a similar way and were used as the data
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set for the models. GTM and PCA were used as dimensionality
reduction techniques to encode all the molecular properties and
fingerprints into two-dimensional spaces that could be visualized
easily. All the models and visualizations were implemented using
the Matlab toolbox Netlab (Nabney, 2002).
RESULTS AND DISCUSSION
The scaffold diversity of the fungal metabolites was compared
to data sets with biological relevance like approved drugs
and commercial libraries available for HTS. In this work the
chemotypes were calculated with the program MEQI (Xu and
Johnson, 2001, 2002), as described in the Section Materials
and Methods. Table S1 shows the most frequent chemotypes
found in the fungal metabolites data set, along with their
chemotype identifier. Interestingly, it was found that this library
has several unique scaffolds not found in the reference data
sets. To further explore the uniqueness of the scaffolds of
the fungal metabolites, we compared the scaffolds from this
data set with the scaffolds of all the compounds found in
ChEMBL, version 22 (Bento et al., 2014; Davies et al., 2015). An
exceptional finding was that out of the 130 different scaffolds
in the fungal metabolites set, 26 were not found in ChEMBL
or any other data set studied in this work. Figure 2 shows
representative scaffolds in the fungal metabolites data set not
found in other data sets. Most of these compounds have been
shown to have cytotoxicity against a variety of human tumor
cell lines. For example, the chemotype TBEMM corresponds
to the cytotoxic compounds Acremonidin C and Acremonidin
A, reported by Ayers et al. (2012). The scaffolds with the
chemotype V7D6X and YVGCT correspond to Palmarumycin
CP3 and Palmarumycin CP4, whose cytotoxic activity has
not been reported. However, their structural similarity with
Palmarumycin CP1 could indicate that the compounds in the
fungal metabolites data set with these scaffolds could have
antibacterial, antifungal and antitumoral activities (Kornienko
et al., 2015). The scaffolds with the codes 8MY2X and ROFC5
belong to new secondary metabolites isolated from Eupenicillium
brefeldianum and Aspergillus fumigatus, respectively, and their
biological activity has not been reported. Figure 2 exemplifies
the considerable structural variation among substances that have
been isolated and characterized from filamentous fungi.
Counts
Table 2 summarizes the number of chemotypes (N) in each
database, the fraction of chemotypes relative to the number of
molecules in each data set (N/M), and the number and fraction
of singletons (Nsing). Based on N/M values, the set of fungal
FIGURE 2 | Unique scaffolds of fungal origin.
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metabolites, containing 223 compounds, has an intermediate
chemotype diversity (N/M = 0.587), similar to the proportion of
chemotypes in the non-anticancer drugs library, containing 1,399
compounds (N/M= 0.572). The set of anticancer drugs has fewer
compounds but the largest proportion of chemotypes relative
to the number of molecules (N/M = 0.921) and the largest
proportion of singletons relative to the number of molecules
(Nsing/M = 0.855). In contrast, GRAS, NATx, and MEGx data
sets with more compounds (Table 1) have the lowest scaffold
diversity with a smaller proportion of chemotypes and singletons.
CSR Curves
CSR curves represent the fraction of compounds in the data set
(y-axis) contained in a fraction of chemotypes (x-axis). A data
set with maximum diversity would contain a different chemotype
for each molecule in the library and the CSR curve would be a
diagonal with an AUC of 0.5. Figure 3 shows the CSR curves
calculated using the chemotypes of all the data sets analyzed in
this study.
The CSR curve for the fungal metabolites indicates this data
set contains more different scaffolds than MEGx, NATx, GRAS,
and the non-anticancer drugs. All these data sets contain at least
six times more compounds than the set with fungal metabolites
(Table 1). The CSR curve for the anticancer drugs is closer to a
diagonal indicating large diversity, while the curves for GRAS
undergoes a sudden increase on its slope indicating this data
set has the lowest chemotype diversity. AUC and the fraction of
chemotypes that contains 50% of the molecules in the data set
(F50) were used to compare the curves for each set quantitatively
(Table 2). An AUC value closer to one indicates low chemotype
diversity and higher F50 values indicate higher diversity. Based on
thesemetrics, the fungalmetabolites aremore diverse thanMEGx
and NATx, commercial data sets with 2,500 natural products and
semi-synthetic compounds and approved non-anticancer drugs,
with an AUC of 0.644 and a F50 = 0.244. As expected, anticancer
drugs showed the lowest AUC and the largest F50 values (0.537
and 0.457, respectively). In agreement with other metrics of
scaffold diversity (i.e., N/M), the GRAS and MEGx libraries had
the highest AUC and lowest F50 values, respectively, indicating
low diversity.
TABLE 2 | Results of different chemotypes diversity analyses on the data
sets.
Database N N/M Nsing Nsing/N Nsing/M AUC F50
Fungal
metabolites
131 0.587 87 0.664 0.390 0.664 0.244
MEGx 935 0.374 642 0.687 0.257 0.781 0.072
NATx 799 0.320 400 0.501 0.160 0.768 0.116
GRAS 238 0.106 150 0.630 0.067 0.926 0.004
Anticancer
drugs
70 0.921 65 0.929 0.855 0.537 0.457
Non-
anticancer
drugs
844 0.572 686 0.813 0.465 0.699 0.157
N, number of chemotypes; M, number of molecules; Nsing, number of singletons; AUC,
area under the curve; F50, fraction of chemotypes that contains 50% of the data set.
Scaled Shannon Entropy (SSE)
SSE was computed to get an idea of the compound distribution
in themost populated chemotypes. For this approach, a SSE value
closer to 1 indicates that compounds are evenly distributed in the
different chemotypes and a low SSE value (i.e., closer to 0) means
all the compounds share the same chemotype. SSE will have its
maximum value only when all chemotypes contain the same
number of compounds, or when each chemotype contains only
one compound. Table 3 summarizes the SSE for the first 70 most
populated chemotypes in each library. The chemotype diversity
of the fungal metabolites is higher (SSE values ranging from
0.942 to 0.967) compared to the non-anticancer drugs and the
FIGURE 3 | Cyclic system retrieval (CSR) curves for the data sets
studied in this work. The curve for the anticancer drugs indicates large
chemotype diversity. In contrast, the curve for GRAS, MEGx, and NATx
suggest less diversity. The curves can be characterized quantitatively by the
area under the curve (AUC) and the fraction of chemotypes required to retrieve
50% of the compounds in the data sets F50 (see Table 2).
TABLE 3 | Scaled Shannon entropy (SSE) results for the first 70
chemotypes and the fraction of compounds contained in the top most
populated chemotypes for the data sets.
Database SSE5 SSE10 SSE20 SSE30 SSE40 SSE50 SSE60 SSE70
Fungal
metabolites
0.967 0.959 0.954 0.954 0.956 0.947 0.943 0.942
MEGx 0.883 0.873 0.869 0.858 0.858 0.858 0.857 0.856
NATx 0.916 0.931 0.938 0.939 0.939 0.938 0.938 0.936
GRAS 0.617 0.57 0.541 0.526 0.517 0.512 0.507 0.501
Anticancer
drugs
0.991 0.964 0.974 0.981 0.986 0.989 0.991 0.992
Non-
anticancer
drugs
0.769 0.750 0.762 0.777 0.789 0.799 0.803 0.809
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commercial libraries NATx and MEGx, which represent larger
data sets containing natural products. Compounds in the library
with anticancer drugs are more evenly distributed among the
chemotypes studied (SSE values higher than 0.960). The least
diverse set is GRAS (SSE values ranging from 0.502 to 0.617).
Of note, the most diverse data sets, the fungal metabolites and
the anticancer drugs, are also the smallest data sets containing
only 223 and 76 compounds, respectively (Table 1). Overall, the
SSE values vary for the rest of the libraries, indicating that that
scaffold diversity decreases in this order: anticancer drugs, fungal
metabolites, NATx, MEGx, non-anticancer drugs, and GRAS.
Interestingly, if the most populated chemotypes in NATx and
MEGx are analyzed, these sets are more diverse than that of the
non-anticancer drugs.
Figure 4 shows the distribution and SSE values of compounds
in the top 70 most populated chemotypes of representative data
sets. Data sets with higher SSE are colored dark red and data
sets with lower SSE are light red. The chemotypes for the fungal
metabolites, Figure 4B, are more evenly distributed after the
top 10 most populated chemotypes and is the second most
diverse data set. Figure 4A shows that anticancer drugs take its
maximum SSE value when all the chemotypes are considered,
indicating there is almost one different chemotype for each
molecule in this data set. MEGx (Figure 4C) has SSE values
FIGURE 4 | Distribution of compounds in the top 70 most populated chemotypes. Values of SSE70 close to 1.0 are dark red and indicate large chemotype
diversity, smaller SSE values are in light red indicating less diversity. (A) Anticancer drugs, (B) fungal metabolites, (C) MEGx, (D) GRAS.
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between 0.883 and 0.856; for this library the first most populated
chemotype contains 195 compounds and the scaffolds are more
evenly distributed after the first 20 most populated chemotypes.
This is also the case with GRAS (Figure 4D), the least diverse set,
measured with SSE, for which the most populated chemotype
contains 1,055 compounds, nearly half of the data set. The
distribution of the compounds in each chemotype and the SSE70
value for the other data sets are shown in Figure S1.
Inter- and Intra-Library Similarities Using
MACCS Keys and Molecular Properties
As stated in the Methods, the inter- and intra- library similarity
was computed using MACCS keys/Soergel-based distance and
molecular properties/Euclidean distance. Figures 5A,B show the
corresponding distance matrices computed with MACCS keys
and molecular properties, respectively. Values along the diagonal
in red represent the intra-library diversity, i.e., the diversity
within the compounds contained in a data set: the least diverse
libraries are in light red while the most diverse libraries are in
dark red. The values in blue represent the inter-library diversity,
i.e., the diversity between the compounds in all the data sets:
the least diverse libraries are in light blue while the most diverse
libraries are in dark blue.
MACCS Keys—Structural Features
In Figure 5A the inter-library similarity matrix, in blue, shows
that the fungal metabolites are structurally different to approved
drugs, with a distance of 0.62 to the anticancer drugs and
a distance of 0.63 to the non-anticancer drugs. Of note, the
fungal metabolites and MEGx have similar structural features,
but both libraries are structurally different to the semi-synthetic
compounds in NATx. NATx is the data set most similar to
approved drugs. This suggests that semi-synthetic compounds
have been modified to be structurally similar to approved drugs,
decreasing their structural similarity to natural products.
In Figure 5A the intra-library similarity in the red diagonal
shows that GRAS and non-anticancer drugs are the most diverse
data sets using MACCs keys (with intra-set distance of 0.61
and 0.63, respectively). In contrast, GRAS is the set with the
lowest scaffold diversity. The reason for this is that 65% of GRAS
molecules are classified into two chemotypes, namely, non-
cyclic structure (49%; 00000), and benzene ring (16.3%; RYLFV).
Nonetheless, having the same chemotype does not imply that
molecules should present the same chemical features, especially
with very common/simple chemotypes as in this case. This is
a good example of how diversity analysis should be conducted
usingmultiple metrics (Singh et al., 2009; Gonzalez-Medina et al.,
2016).
Molecular Properties
According to the distance scores of the molecular properties, the
fungal metabolites intra-library molecular properties, Figure 5B
red diagonal, are more diverse than the properties of non-
anticancer drugs, GRAS and NATx, with a Euclidian distance
equal to 2.73. Comparing the fungal metabolites inter-library
distances to the lowest inter and intra-library distances obtained
for other data sets, e.g., GRAS intra-library similarity with
FIGURE 5 | Intra and inter-library similarity. The diagonal in red depicts
intra-library comparisons, i.e., the similarity between the compounds in a data
set. Dark red scores indicate large distance or low similarity, while light red
colors indicate small distance or high similarity. The matrix in blue depicts
inter-library similarity comparisons, i.e., the similarity between the compounds
in the data sets. Dark blue scores indicate large distance or low similarity, while
white or light blue colors indicate small distance or high similarity. (A) Soergel
distance using MACCS keys (166-bit) fingerprints. (B) Euclidean distance
function using molecular properties.
a value of 1.00 or NATx and non-anticancer drugs with an
inter-library similarity of 1.90, the fungal metabolites have
diverse molecular properties compared to the other data
sets. Of note, the inter-library results, in a blue scale, show
that the fungal metabolites have the largest dissimilarity with
GRAS, which has been previously demonstrated to contain
smaller compounds with less HBD, HBA, MW, and TPSA
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than the fungal metabolites (Gonzalez-Medina et al., 2016).
Table S2 contains the statistics of each property for all the
data sets. Figure 5B also shows that NATx has the lowest
inter-data set distance (more similar) to the rest of the
data sets studied and GRAS is the least similar (i.e., the
most distant) to the other libraries. Interestingly, approved
anticancer drugs and GRAS present the largest distance to the
other data sets, with an added distance of 28.72 and 27.37,
respectively. As previously discussed (Gonzalez-Medina et al.,
2016), compounds in the data set containing approved anticancer
drugs show the largest distance (dissimilarity) to the non-
anticancer drugs.
Global Diversity Analysis with Consensus
Diversity Plots (CDPs)
Figure 6 shows a CDP, which compares the global structural
diversity of all data sets, by plotting MACCs keys/Soergel-
based distance in the x axis and AUC in the y axis. The
size of the data points represents the relative size of each
data set (Table 1) and the color of each data point represents
the molecular properties diversity (Figure 5B). Remarkably,
the fungal metabolites, a data set with 223 compounds, had
more different scaffolds than data sets with 2,500 compounds,
such as MEGx and NATx; the fungal metabolite dataset is
on average, more structurally diverse than MEGx and more
diverse than NATx when considering molecular properties. The
fungal metabolites and the anticancer drugs are located in
the yellow quadrant, indicating high scaffold diversity but low
structure (fingerprint-based) diversity. Furthermore, the data
point in red, representing the fungal metabolites, indicates this
data has diverse molecular properties. Overall, non-anticancer
drugs, in the red quadrant, are the most structurally diverse
(with a Soergel-based distance of 0.63 and an AUC of 0.699).
However, non-anticancer drugs in orange/brown are less diverse
by molecular properties than the fungal isolates. GRAS, in the
blue quadrant, is themost diverse library when structural features
are taken into account, but the compounds in this data set
have low molecular properties diversity. Compared to the other
data sets, MEGx, in the white quadrant, is the least structural
diverse. The molecular properties diversity is independent of
the structural diversity or the size of the libraries, that is,
small data sets can be both structurally diverse and diverse by
their molecular properties, or structurally diverse but with low
molecular properties diversity.
Visual Representation of the Chemical
Space
Figure 7 depicts the visual representation of the six data sets
generated with GTM using the structural features MACCS keys.
The fungal metabolites occupy similar areas of the structural
space of MEGx, which is in agreement with the results observed
on Figure 5A. The clusters of compounds in the structural
space of the fungal metabolites are in different areas of the
space of most of the approved drugs, and particularly, from
the approved anticancer drugs. This is also in line with the
results on Figure 5A and could give the notion that different
FIGURE 6 | Consensus Diversity Plot comparing the diversity of six
data sets. The structural diversity was defined with MACCs keys
fingerprints/Soergel-based distance and area under curve (AUC). The
quadrants color codes are as follows: red, indicates the library is diverse
considering its scaffolds and/or side chains; white, the library is not diverse;
blue, the library is diverse if the chemical features of the entire molecule are
considered and/or side chains contribute significantly to the diversity; yellow,
the scaffolds of the molecules are the main factor contributing to the diversity
and/or this set contains mostly rings with few side chains. Data points are
colored by the diversity of the physicochemical properties of the data set as
measured by the Euclidean distance of six properties of pharmaceutical
relevance. The distance is represented with a continuous color scale from red
(more diverse), to orange/brown (intermediate diversity) to green (less diverse).
The relative size of the data set is represented with the size of the data point:
smaller data points indicate compound data sets with fewer molecules.
A value of 0.75 for AUC and the median value of the MACCs keys
fingerprints/Soergel-based distance were used to set the quadrants.
structural features found in the fungal metabolites are not
found in the approved drugs. Interestingly, semi-synthetic
compounds (NATx) are in different areas of the structural space
of natural products, compared with the fungal metabolites and
MEGx. Approved non-anticancer drugs and MEGx are the
most dispersed, whereas GRAS seems to be more clustered
in a high-density region that contains some compounds from
MEGx.
Figure S2 depicts the visual representation of the chemical
space generated with GTM using physicochemical properties.
The fungal metabolites form small clusters and occupy similar
areas of the physicochemical space ofMEGx, NATx, and the non-
anticancer drugs, with a few exceptions found on the bottom left
of the fungal metabolites plot, but occupy different areas than
the anticancer drugs. NATx and GRAS are less distributed in the
chemical space. This result is in agreement with Figure 5B.
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FIGURE 7 | Visual representation of the chemical space of the six data sets generated with Generative Topographic Mapping (GTM) using MACCS
keys fingerprints.
The visualization generated with PCA using MACCS keys
fingerprints (Figure S3) generated clusters of molecules easier
to interpret. The results obtained with this representation
were in line with the results obtained with GTM. Based on
the structural features encoded by MACCS keys, some fungal
metabolites are in the same region as the approved anticancer
and non-anticancer drugs. However, most of the molecules in
the data sets containing natural products, MEGx and the fungal
metabolites, are clustered together in a region separated from
the other data sets. Figure S4 depicts the visualization of the six
molecular properties (described in the Materials and Methods
Section) using PCA: the fungal metabolites are in similar regions
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as the non-anticancer drugs, with a few compounds dispersed
similarly to MEGx. Anticancer drugs are the most spread (more
diverse), while GRAS is more constrained in to specific areas
of the chemical space. These results are also in agreement with
results derived from Figure 5B.
CONCLUSIONS
Using computational-driven approaches, this work reports the
structural diversity and scaffold content of a set of 223 fungal
metabolites isolated and characterized in discovery projects
funded by the USA National Cancer Institute and the Mexican
National Research Council of Science and Technology. Generally
speaking, most of these compounds were isolated while pursuing
new anticancer drug leads. The structural diversity of the
fungal metabolites was quantified using three complementary
approaches: Cyclic Systems Retrieval curves, Shannon entropy,
and molecular fingerprints. The dataset of fungal metabolites was
compared to datasets that represent synthetic, semi-synthetic,
and natural products commercially available for HTS and
approved drugs. It was concluded that most of the chemical
structures of the fungal metabolites are cyclic compounds with
few side chains. The diversity analysis showed that the set of
fungal secondary metabolites herein studied is more diverse than
commercial libraries with natural products and semi-synthetic
compounds despite the fact that the reference collections
are expected to be diverse and contain more compounds.
Moreover, the fungal dataset was developed mostly via pursuing
leads that were cytotoxic to cancer cell lines; if the diversity
of the targets were to be expanded, the resultant chemical
diversity may expand as well. Moreover, the fungal metabolites
have a large proportion of different and unique scaffolds
not found in the other reference sets, including ChEMBL.
Additionally, visualizations of the chemical space, based both
on molecular fingerprints and molecular properties, revealed
that the fungal metabolites cover different areas of chemical
space when compared to that of approved drugs, offering the
possibility to expand the medicinally-relevant chemical space.
For example, this diverse data set could be used for HTS to
find new hits with new scaffolds and diverse properties. The
high and unique scaffold diversity of fungal metabolites revealed
in this work, in addition to the high structural complexity
and balanced molecular properties revealed in previous studies
(Greve et al., 2010; El-Elimat et al., 2012; Cragg and Newman,
2013; Gonzalez-Medina et al., 2016), further supports fungal
metabolites as a promising sources of novel compounds for drug
discovery.
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